Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial
Johnsen, E., Kroken, R. A., Løberg, E. M., Rettenbacher, M., Joa, I., Larsen, T. K., … & Bartz-Johannessen, C. (2020). Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. The Lancet Psychiatry, 7(11), 945-954.
Head to head trials of antipsychotic medications are rare. This European trial found that amisulpiride was more efficacious than aripiprazole or olanzapine for reducing symptoms of psychosis in adults with schizophrenia-spectrum disorders. There were few differences in side effects between the groups.